dc.creator | Villegas Lama, Isabel | es |
dc.creator | Rosillo Ramírez, María de los Ángeles | es |
dc.creator | Alarcón de la Lastra Romero, Catalina | es |
dc.creator | Vázquez Román, María Victoria | es |
dc.creator | Llorente, María | es |
dc.creator | Sánchez, Susana | es |
dc.creator | Fernández Campos, Francisco | es |
dc.date.accessioned | 2021-02-12T09:59:24Z | |
dc.date.available | 2021-02-12T09:59:24Z | |
dc.date.issued | 2021-01 | |
dc.identifier.citation | Villegas Lama, I., Rosillo Ramírez, M.d.l.Á., Alarcón de la Lastra Romero, C., Vázquez Román, M.V., Llorente, M., Sánchez, S. y Fernández Campos, F. (2021). Amoxicillin and Clarithromycin Mucoadhesive Delivery System for Helicobacter pylori Infection in a Mouse Model: Characterization, Pharmacokinetics, and Efficacy. Pharmaceutics, 13 (2), 153. | |
dc.identifier.issn | 1999-4923 | es |
dc.identifier.uri | https://hdl.handle.net/11441/104881 | |
dc.description.abstract | Helicobacter pylori is the main pathogen responsible for gastric ulcers and a predisposing
factor of stomach cancer. Although current treatment is usually successful, it requires high doses and
frequent administration. An innovative mucoadhesive system (Mucolast®) loaded with amoxicillin
and clarithromycin is proposed to improve the efficacy of treatment against H. pylori. The drug
product was optimized based on its viscoelastic properties to obtain long-term stability of the
vehicle. The drug release mechanisms were different for both antibiotics based on their solubilization
status. A systemic and stomach pharmacokinetic profile was obtained after three different doses
were administered to mice, obtaining similar systemic exposure levels but an increase in drug
concentration in the stomach. The efficacy results in mice infected with H. pylori also demonstrated
the superiority of the antibiotics when administered in Mucolast®, as shown by the bacterial count in
stomach tissue and under histopathological and biochemical evaluation. The proposed treatment
was efficacious and safe and is presented as a realistic alternative to current treatment options to
improve patient compliance and to reduce bacterial resistance. | es |
dc.description.sponsorship | Ministerio de Ciencia e Innovación. Gobierno de España (programa RETOS)-RTC-2015-4437-1 | es |
dc.format | application/pdf | es |
dc.format.extent | 25 p. | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.relation.ispartof | Pharmaceutics, 13 (2), 153. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Helicobacter pylori | es |
dc.subject | mucoadhesive | es |
dc.subject | clarithromycin | es |
dc.subject | amoxicillin | es |
dc.subject | mice | es |
dc.subject | pharmacokinetics | es |
dc.subject | Mucolast® | es |
dc.title | Amoxicillin and Clarithromycin Mucoadhesive Delivery System for Helicobacter pylori Infection in a Mouse Model: Characterization, Pharmacokinetics, and Efficacy | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Farmacología | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Citología e Histología Normal y Patológica | es |
dc.relation.projectID | RTC-2015-4437-1 | es |
dc.relation.publisherversion | https://doi.org/10.3390/pharmaceutics13020153 | es |
dc.identifier.doi | 10.3390/pharmaceutics13020153 | es |
dc.journaltitle | Pharmaceutics | es |
dc.publication.volumen | 13 | es |
dc.publication.issue | 2 | es |
dc.publication.initialPage | 153 | es |
dc.contributor.funder | Ministerio de Ciencia e Innovación (MICIN). España | es |